HOME › DRUGS › PRALSETINIB
ACTIVE SUBSTANCE / INN

PRALSETINIB

Brand name(s): GAVRETO, Gavreto
FDA LISTED
EMA LISTED
PRESCRIPTION
WITHDRAWN
Carcinoma, Non-Small-Cell Lung
NDA214701
ACTIVE SUBSTANCE
Pralsetinib
REGULATORS
FDA · EMA
SPONSORS / MAH
Blueprint Medicines (Netherlands) B.V., BLUEPRINT MEDICINES
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
GAVRETONDA214701BLUEPRINT MEDICINESPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
GavretoBlueprint Medicines (Netherlands) B.V.Withdrawn18/11/2021Carcinoma, Non-Small-Cell Lung

FULL INTELLIGENCE ON PRALSETINIB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →